Handa Pharmaceuticals Statistics
Total Valuation
Handa Pharmaceuticals has a market cap or net worth of TWD 11.05 billion. The enterprise value is 8.56 billion.
Market Cap | 11.05B |
Enterprise Value | 8.56B |
Important Dates
The next estimated earnings date is Thursday, December 26, 2024.
Earnings Date | Dec 26, 2024 |
Ex-Dividend Date | Apr 18, 2024 |
Share Statistics
Handa Pharmaceuticals has 141.09 million shares outstanding. The number of shares has increased by 7.81% in one year.
Shares Outstanding | 141.09M |
Shares Change (YoY) | +7.81% |
Shares Change (QoQ) | +0.01% |
Owned by Insiders (%) | 1.21% |
Owned by Institutions (%) | 0.08% |
Float | 139.37M |
Valuation Ratios
The trailing PE ratio is 24.15 and the forward PE ratio is 4.90.
PE Ratio | 24.15 |
Forward PE | 4.90 |
PS Ratio | 11.23 |
PB Ratio | 3.81 |
P/FCF Ratio | 14.83 |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 15.82, with an EV/FCF ratio of 11.49.
EV / Earnings | 18.92 |
EV / Sales | 8.79 |
EV / EBITDA | 15.82 |
EV / EBIT | 16.12 |
EV / FCF | 11.49 |
Financial Position
The company has a current ratio of 17.75, with a Debt / Equity ratio of 1.27.
Current Ratio | 17.75 |
Quick Ratio | 17.71 |
Debt / Equity | 1.27 |
Debt / EBITDA | 0.07 |
Debt / FCF | 0.05 |
Interest Coverage | 2,294.41 |
Financial Efficiency
Return on equity (ROE) is 21.92% and return on invested capital (ROIC) is 15.71%.
Return on Equity (ROE) | 21.92% |
Return on Assets (ROA) | 14.66% |
Return on Capital (ROIC) | 15.71% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.43 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -50.44% in the last 52 weeks. The beta is 1.43, so Handa Pharmaceuticals's price volatility has been higher than the market average.
Beta (5Y) | 1.43 |
52-Week Price Change | -50.44% |
50-Day Moving Average | 88.85 |
200-Day Moving Average | 137.97 |
Relative Strength Index (RSI) | 35.55 |
Average Volume (20 Days) | 242,811 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Handa Pharmaceuticals had revenue of TWD 972.97 million and earned 452.32 million in profits. Earnings per share was 3.24.
Revenue | 972.97M |
Gross Profit | 971.68M |
Operating Income | 525.42M |
Pretax Income | 587.13M |
Net Income | 452.32M |
EBITDA | 529.31M |
EBIT | 525.42M |
Earnings Per Share (EPS) | 3.24 |
Balance Sheet
The company has 2.53 billion in cash and 36.89 million in debt, giving a net cash position of 2.49 billion or 17.66 per share.
Cash & Cash Equivalents | 2.53B |
Total Debt | 36.89M |
Net Cash | 2.49B |
Net Cash Per Share | 17.66 |
Equity (Book Value) | 2.90B |
Book Value Per Share | 20.56 |
Working Capital | 2.61B |
Cash Flow
In the last 12 months, operating cash flow was 746.52 million and capital expenditures -1.68 million, giving a free cash flow of 744.84 million.
Operating Cash Flow | 746.52M |
Capital Expenditures | -1.68M |
Free Cash Flow | 744.84M |
FCF Per Share | 5.28 |
Margins
Gross margin is 99.87%, with operating and profit margins of 54.00% and 46.49%.
Gross Margin | 99.87% |
Operating Margin | 54.00% |
Pretax Margin | 60.34% |
Profit Margin | 46.49% |
EBITDA Margin | 54.40% |
EBIT Margin | 54.00% |
FCF Margin | 76.55% |
Dividends & Yields
This stock pays an annual dividend of 1.00, which amounts to a dividend yield of 1.22%.
Dividend Per Share | 1.00 |
Dividend Yield | 1.22% |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | 31.19% |
Buyback Yield | -7.81% |
Shareholder Yield | -6.59% |
Earnings Yield | 4.14% |
FCF Yield | 6.74% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |